| Model Number |
VACDSP |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Failure of Implant (1924)
|
| Date of Event |
01/25/2020
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Additional device information: activ.A.C.¿ therapy system serial number (b)(4) and unique identifier (udi) (b)(4).Device manufacture date: activ.A.C.¿ therapy system: 15-oct-2019.Based on information provided, it cannot be determined that the alleged graft failure is related to the v.A.C.® simplace¿ dressing.Device labeling, available in print and online, states: continuous therapy is also generally recommended for patients at increased risk of bleeding, highly exudating wounds, fresh flaps and grafts, and wounds with acute enteric fistulae.Continuous therapy for duration of 7 days with no dressing changes is also generally recommended for use of v.A.C.® therapy with a new graft placement.Apply v.A.C.® dressing immediately after graft placement and begin therapy as soon as possible.When using v.A.C.® granufoam¿ dressings, a non-adherent dressing should be placed directly over the graft / tissue.In general, the pressure setting used to prepare the recipient bed before grafting should be continued after grafting.Continuous therapy should be used to provide a constant bolster.
|
| |
|
Event or Problem Description
|
|
On (b)(6) 2020, the following information was reported to kci by the patient: on (b)(6) 2020, the patient's skin graft was allegedly removed when the nurse changed the v.A.C.® simplace¿ dressing.On 06-feb-2020, the following information was reported to kci by the nurse: the graft was reapplied on (b)(6) 2020 and v.A.C.® therapy resumed.On 18-feb-2020, a device history record review for v.A.C.® simplace¿ dressing lot number 6829990v007 was completed.All end release testing of the product and packaging met specifications.A device evaluation of activ.A.C.¿ therapy unit is currently pending completion.
|
| |
|
Additional Manufacturer Narrative
|
|
Mdr-3009897021-2020-00065 submitted on 26-feb-2020 noted the following: b3: date of event: (b)(6) 2020.B4: date of this report: 26-jan-2020.B5: describe event or problem: a device evaluation of activ.A.C.¿ therapy unit is currently pending completion.H3: device evaluated by manufacturer?: no: device evaluation anticipated, but not yet begun.Correction: b3: date of event: (b)(6) 2020.B4: date of this report: 26-feb-2020.B5: describe event or problem: the v.A.C.® simplace¿ dressing was not returned; therefore, a device evaluation could not be performed.H3: device evaluated by manufacturer?: no: other - device not returned.; not returned to manufacturer h10: corrected data: h3: other (code unspecified, describe in h10): the v.A.C.® simplace¿ dressing was not returned; therefore, a device evaluation could not be performed.Based on the corrections, kci's assessment remains the same; it cannot be determined that the alleged graft failure is related to the v.A.C.® simplace¿ dressing.
|
| |
|
Event or Problem Description
|
|
The v.A.C.® simplace¿ dressing was not returned; therefore, a device evaluation could not be performed.
|
| |
|
Search Alerts/Recalls
|